Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 5,517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more

Conditions: Healthy, Hepatitis C, Chronic
Interventions: TG-2349, placebo; Drug
Lead sponsor: TaiGen Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions: Lamotrigine and Bupropion, Placebo; Drug
Lead sponsor: Dent Neuroscience Research Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Amherst, New York

Conditions: Rheumatoid Arthritis
Interventions: GLPG0634, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 28
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Nutriceutical formulation, Placebo; Dietary Supplement · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more

Conditions: Acute Coronary Syndrome
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 186
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more

Conditions: Rheumatoid Arthritis
Interventions: INCB028050, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more

Conditions: Sleep Apnea, Obstructive
Interventions: Ramelteon or Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 5
States / cities: Birmingham, Alabama • Palm Springs, California • Santa Monica, California + 2 more

Conditions: Healthy Women
Interventions: Essential Amino Acid+, Non-Calorie Placebo, High intensity Interval Training, No Exercise; Dietary Supplement · Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteoarthritis of the Knee
Interventions: ketoprofen Patch, Placebo Patch; Drug · Other
Lead sponsor: Hisamitsu Pharmaceutical Co., Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 31 more

Conditions: Depression, Postpartum
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 68
States / cities: Scottsdale, Arizona • Bentonville, Arkansas • Anaheim, California + 62 more

Conditions: Cardiovascular Disease
Interventions: Rimonabant, Placebo (for Rimonabant); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 18,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Alcohol Drinking
Interventions: Saracatinib, Placebos; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Phobic Disorders
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: La Jolla, California • Hartford, Connecticut • Orlando, Florida + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: South Miami, Florida

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Matching Placebo, IW-1973; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Conditions: HIV
Interventions: Maraviroc (UK-427,857), Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more

Conditions: Bladder Cancer
Interventions: SUTENT, Placebo; Drug · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Autistic Disorder, Behavioral Symptoms
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 55
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more

Search by objective public record fields.

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Lamotrigine and Bupropion for Meniere's Disease

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

Daily Upgrade Trial

HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Saracatinib and Alcohol Drinking

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

A Study of TAK-951 in Healthy Adults

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)